{"id":238,"date":"2017-02-08T18:20:05","date_gmt":"2017-02-08T16:20:05","guid":{"rendered":"http:\/\/kogital.com\/clients\/leventkabasakal\/?page_id=238"},"modified":"2019-03-04T13:02:56","modified_gmt":"2019-03-04T11:02:56","slug":"hedeflenmis-molekuler-radyonuklid-kanser-tedavisi","status":"publish","type":"page","link":"https:\/\/www.leventkabasakal.com\/en\/radyoiyot-tedavisi\/hedeflenmis-molekuler-radyonuklid-kanser-tedavisi\/","title":{"rendered":"(Turkish) HEDEFLENM\u0130\u015e MOLEK\u00dcLER RADYON\u00dcKL\u0130D KANSER TEDAV\u0130S\u0130"},"content":{"rendered":"<p>Cerrahi, radyoterapi ve kemoterapi kanser hastal\u0131klar\u0131n\u0131n standart tedavisidir. E\u011fer hastal\u0131k v\u00fccuda yay\u0131lm\u0131\u015f ise kemoterapi tek se\u00e7enek olarak kalmaktad\u0131r. Ancak kemoterapi ila\u00e7lar\u0131 sadece kanser dokusunu de\u011fil t\u00fcm normal dokular\u0131 da etkiler. Bu nedenle ciddi istenmeyen, ya\u015fam kalitesini de bozan yan etkiler ortaya \u00e7\u0131kar. B\u00f6yle durumlarda hastaya verilen ila\u00e7 dozu azalt\u0131l\u0131r. Ancak bunun sonucu hastal\u0131\u011f\u0131jn tedavi edilememesidir. <strong>Hedeflenmi\u015f molek\u00fcler radyon\u00fcklid kanser tedavisi<\/strong> (molecular targetted radionuclide cancer therapy), \u00f6zellikle v\u00fccutta yay\u0131lm\u0131\u015f kanser hastal\u0131klar\u0131nda giderek \u00f6nem kazanmaktad\u0131r. Hedeflenmi\u015f radyon\u00fcklit (atom) tedavisinin \u00f6zelli\u011fi molek\u00fcl\u00fcn hastal\u0131\u011fa y\u00f6nlendirilmesi ve di\u011fer normal dokular\u0131n tedaviden olumsuz etkilenmemesidir. Di\u011fer bir deyi\u015fle hedeflenmi\u015f tedavi asl\u0131nda hedefe tam isabet ettirme y\u00f6ntemidir. Hedeflenmi\u015f atom tedavisinde radyoaktif maddeyi radyofarmas\u00f6tik denilen ila\u00e7lar ger\u00e7ekle\u015ftirir. Radyofarmas\u00f6tikler yandaki \u015fekilde g\u00f6sterildi\u011fi gibi kanserli dokunun belli bir b\u00f6lgesinde giden molek\u00fclle birlikte radyoaktif maddenin ta\u015f\u0131nmas\u0131n\u0131 sa\u011flarlar.\u00a0Radyofarmas\u00f6tik teknolojisinde son y\u0131llarda b\u00fcy\u00fck at\u0131l\u0131mlar yap\u0131lm\u0131\u015f ve \u00f6nemli geli\u015fmeler olmu\u015ftur.<\/p>\n<p>Avrupa Birli\u011fi de bu geli\u015fmelere sessiz kalmam\u0131\u015f ve 21 \u00fclkeden 100 den fazla bilim adam\u0131n\u0131n kat\u0131ld\u0131\u011f\u0131 bir &#8220;e-COST action&#8221; (<strong>European Cooperation for Science and Technology<\/strong>) geli\u015ftirmi\u015ftir. Milyonlarca Avroluk bu harekete de \u00fclkemizden Prof. Dr. Levent Kabasakal davet edilmi\u015ftir. Bu COST hareketinin amac\u0131 \u00e7ok say\u0131daki, n\u00fckleer t\u0131p, onkoloji, cerrahi, fizik, biyokimya, kimya uzman\u0131n\u0131 bir araya getirip, bilgi ve teknoloji al\u0131\u015fveri\u015fini yaparak kanser tedavisinde kullan\u0131lacak yeni molek\u00fcllerin geli\u015ftirilmesini sa\u011flamakt\u0131r. 2008 y\u0131l\u0131 Mart ay\u0131ndan bu yana Prof. Dr. Levent Kabasakal BM067 nolu &#8220;Targetted Radionuclide Therapy&#8221; isimli COSt hareketinin y\u00f6netim komitesinde g\u00f6rev yapmaktad\u0131r.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cerrahi, radyoterapi ve kemoterapi kanser hastal\u0131klar\u0131n\u0131n standart tedavisidir. E\u011fer hastal\u0131k v\u00fccuda yay\u0131lm\u0131\u015f ise kemoterapi tek se\u00e7enek olarak kalmaktad\u0131r. Ancak kemoterapi ila\u00e7lar\u0131 sadece kanser dokusunu de\u011fil t\u00fcm normal dokular\u0131 da etkiler. Bu nedenle ciddi istenmeyen, ya\u015fam kalitesini de bozan yan etkiler ortaya \u00e7\u0131kar. B\u00f6yle durumlarda hastaya verilen ila\u00e7 dozu azalt\u0131l\u0131r. Ancak bunun sonucu hastal\u0131\u011f\u0131jn tedavi edilememesidir. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":240,"parent":28,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","footnotes":""},"class_list":["post-238","page","type-page","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/www.leventkabasakal.com\/en\/wp-json\/wp\/v2\/pages\/238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.leventkabasakal.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.leventkabasakal.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.leventkabasakal.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.leventkabasakal.com\/en\/wp-json\/wp\/v2\/comments?post=238"}],"version-history":[{"count":1,"href":"https:\/\/www.leventkabasakal.com\/en\/wp-json\/wp\/v2\/pages\/238\/revisions"}],"predecessor-version":[{"id":558,"href":"https:\/\/www.leventkabasakal.com\/en\/wp-json\/wp\/v2\/pages\/238\/revisions\/558"}],"up":[{"embeddable":true,"href":"https:\/\/www.leventkabasakal.com\/en\/wp-json\/wp\/v2\/pages\/28"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.leventkabasakal.com\/en\/wp-json\/wp\/v2\/media\/240"}],"wp:attachment":[{"href":"https:\/\/www.leventkabasakal.com\/en\/wp-json\/wp\/v2\/media?parent=238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}